Pharming Group N.V annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Debt-to-Assets Ratio Growth & History (PHAR)
Pharming Group N.V's debt-to-assets ratio was 0.04 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.04 | −0.04 | −52.61% |
| 2024 | 2024-12-31 | 0.07 | 0.00 | +4.51% |
| 2023 | 2023-12-31 | 0.07 | −0.01 | −8.52% |
| 2022 | 2022-12-31 | 0.08 | 0.03 | +48.89% |
| 2021 | 2021-12-31 | 0.05 | 0.03 | +115.71% |
| 2020 | 2020-12-31 | 0.02 | −0.00 | −11.90% |
| 2019 | 2019-12-31 | 0.03 | — | — |
Pharming Group N.V quarterly debt-to-assets ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.24 | −0.05 | −15.81% |
| Q1 2026 | 2026-03-31 | 0.24 | — | — |
| Q4 2025 | 2025-12-31 | 0.04 | −0.04 | −52.61% |
| Q3 2025 | 2025-09-30 | 0.28 | — | — |
| Q2 2025 | 2025-06-30 | 0.29 | — | — |
| Q4 2024 | 2024-12-31 | 0.07 | 0.00 | +4.51% |
| Q4 2023 | 2023-12-31 | 0.07 | −0.01 | −8.52% |
| Q4 2022 | 2022-12-31 | 0.08 | 0.03 | +48.89% |
| Q4 2021 | 2021-12-31 | 0.05 | 0.03 | +115.71% |
| Q4 2020 | 2020-12-31 | 0.02 | — | — |
Pharming Group N.V debt-to-assets ratio trends
Over the last five fiscal years, Pharming Group N.V's debt-to-assets ratio increased from 0.02 to 0.04, a change of 0.01. The latest reported quarter, Q2 2026, shows 0.24.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...